Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Operating Expenses: 2009-2024

Historic Operating Expenses for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Dec 2024 value amounting to $296.6 million.

  • Catalyst Pharmaceuticals' Operating Expenses rose 5.58% to $82.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $319.4 million, marking a year-over-year increase of 11.49%. This contributed to the annual value of $296.6 million for FY2024, which is 4.75% down from last year.
  • According to the latest figures from FY2024, Catalyst Pharmaceuticals' Operating Expenses is $296.6 million, which was down 4.75% from $311.4 million recorded in FY2023.
  • Over the past 5 years, Catalyst Pharmaceuticals' Operating Expenses peaked at $311.4 million during FY2023, and registered a low of $77.8 million during FY2020.
  • Its 3-year average for Operating Expenses is $240.1 million, with a median of $296.6 million in 2024.
  • In the last 5 years, Catalyst Pharmaceuticals' Operating Expenses surged by 177.13% in 2023 and then decreased by 4.75% in 2024.
  • Over the past 5 years, Catalyst Pharmaceuticals' Operating Expenses (Yearly) stood at $77.8 million in 2020, then increased by 13.73% to $88.4 million in 2021, then grew by 27.04% to $112.4 million in 2022, then surged by 177.13% to $311.4 million in 2023, then fell by 4.75% to $296.6 million in 2024.